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Abstract
Background: In patients treated with vagus nerve stimulation (VNS) for drug resistant epilepsy (DRE), up to 1/3 of patients will eventually not respond to 
the therapy. As VNS therapy requires surgery for device implantation, prediction of response prior to surgery is desirable. We hypothesized that 
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neurophysiological investigations related to the mechanisms of action of VNS may help to differentiate VNS responders from non-responders prior to the 
initiation of therapy. 
Methods: In a prospective series of DRE patients, polysomnography (PSG), heart rate variability (HRV) and cognitive event related potentials (ERPs) were 
recorded. PSG and HRV were repeated after one year of treatment with VNS. PSG, HRV and ERPs were compared between VNS-responders (≥ 50% 
reduction in seizure frequency) and non-responders.
Results:  15/30 patients became VNS responders after 1 year of VNS treatment. Prior to treatment with VNS, the amount of deep sleep (NREM 3), the 
HRV high frequency (HF) power and the P3b amplitude were significantly different in responders compared to non-responders (p=0.007; p=0.001; 
p=0.03). 
Conclusion: We found three neurophysiological parameters, NREM 3, HRV HF and P3b amplitude, to be significantly different in DRE patients who 
became responders to VNS treatment prior to initiation of their treatment with VNS. These non-invasive recordings may be used as characteristics for 
response in future studies and help avoid unsuccessful implantations. Mechanistically these findings may be related to changes in brain regions involved in 
the so-called vagal afferent network.
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
INTRODUCTION
Vagus nerve stimulation (VNS) (VNS Therapy Systems, Livanova, Houston, Texas, USA) is indicated for treatment of drug resistant epilepsy (DRE) 
patients who are unsuitable candidates for resective epilepsy surgery. Since its approval in 1997, over 100,000 patients have been implanted worldwide. The 
chances of > 50% seizure reduction range from 25-55% with a tendency for increased seizure control with time.(1, 2) An important drawback of the 
therapy in clinical practice is that predictors for response have not been identified while up to one third of patients do not respond to VNS. Retrospective 
studies with large sample sizes investigating the correlation between patient characteristics and outcome have been disappointing. Studies on age and 
duration of epilepsy, etiology and ictal onset zone in correlation to VNS response show inconsistencies and none of these described ‘predictors’ for VNS 
response allow to make predictions on an individual basis. (3-5)
Investigation of patients based on the current knowledge of the mechanism of action (MOA) of VNS may provide a more rational approach to identify 
patients’ characteristics for response. Research on the underlying neurobiology of VNS indicates that the seizure suppressing effects are attributed to 
bottom-up targeting of crucial central nervous system structures through the afferent projections of the cervical vagus nerve, the so-called ‘vagal afferent 
network’ previously described in mechanistic reviews.(6, 7) Vagal afferents primarily project to the brainstem nucleus tractus solitarius (NTS), which in turn 
sends fibers among others to the hypothalamus and other brainstem nuclei such as the locus coeruleus (LC) and the parabranchial nucleus; these nuclei are 
important in modulating the activity of subcortical and cortical epileptic circuitry involving the thalamus and limbic structures. The LC is the main 
noradrenergic nucleus of the central nervous system and implied in the arousal promoting system of the brain. (8) Preclinical and clinical studies have 
demonstrated a crucial role of the LC-noradrenergic (LC-NE) system in the seizure suppressive effects of VNS.(9-11) We previously demonstrated that ≥ 
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18 months of VNS treatment induced a significant increase of the P3 event related potential amplitude in VNS responders compared to non-responders. 
(12) The P3 reflects attentional and memory processes and the P3b component is correlated to LC-NE activity, whereas the P3a component reflects 
dopaminergic/frontal processes. (13) The timing and variability of the heart beat is controlled and modulated by sympathetic and parasympathetic inputs 
from the brain. The brain areas involved in this cortical control mechanism of heart rate variability (HRV) (anterior cingulate, amygdala, LC) belong to the 
‘vagal afferent network’. (14) An impaired HRV has already been described in DRE patients for more than 25 years.(15) HRV can be measured in time 
domain, quantifying the amount of variability, and frequency domain, estimating the distribution of HRV by assessing the low frequency (LF power) and 
high frequency (HF power) spectral content. (16) The anterior hypothalamus where the ventrolateral preoptic (VLPO) nucleus is situated is responsible for 
the induction and maintenance of sleep.(17) During non rapid eye movement (NREM) sleep stages the LC-NE system, a wakefulness promoting area is 
still active but on a decreased level. (18) The LC provides direct input to the hypothalamus and to thalamo-cortical connections, where a decreased 
connectivity is described during sleep in healthy individuals. (19, 20) 
The LC, amygdala, hypothalamus and thalamo-cortical circuit are brain regions both involved in generation and regulation of P3, HRV and sleep and 
belonging to the ‘vagal afferent network’. (Figure 1) Therefore we prospectively performed investigations of P3, HRV and sleep prior to and one year 
following VNS implantation and correlated this with long-term VNS response. We hypothesized that these non-invasive neurophysiological investigations 
related to the MOA of VNS may help to differentiate VNS responders from non-responders prior to implantation and therefore serve as clinical 
characteristics for response prediction. 
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MATERIALS AND METHODS
Subjects and VNS
Forty-four adult DRE patients were implanted with VNS between 09/2013 and 01/2017 at the Reference Center for Refractory Epilepsy in Ghent 
University Hospital, Belgium. Inclusion criteria for this prospective study were adult DRE patients and selection for VNS treatment after pre-surgical 
evaluation. Exclusion criteria were severe mental impairment, VNS implantation complications, VNS as a part of status epilepticus treatment. Patients were 
informed about the study and they or their caregiver signed informed consent. This prospective study was approved by the ethics committee of Ghent 
University Hospital (EC UZG 2013/094). 
From 09/2013 to 09/2016 Demipulse Model 103 and from 10/2016 Aspire Model 106 were implanted subcutaneously below the left clavicle with 
stimulation of the left vagus nerve. Two/four weeks later, patients were admitted for a 48 hours video-electroencephalogram (EEG) monitoring with 
polysomnography (PSG) in the first night of admission (= baseline). After the first night, VNS was started with the following parameters: output current 
0.25mA (0.5mA if tolerated), signal frequency 30Hz, pulse-width 500μs, duty cycle: 30s ON and 5-10min OFF-time. During the first year of treatment 
(every 6-8 weeks), current output was ramped up (steps of 0.25mA) to the maximum tolerable stimulation (max 3mA) then the duty cycle was adjusted. 
Stimulation parameters in VNS responders were: current output (0.75mA - 2.5mA), duty cycle (10min - 5 min OFF), stimulation duration 30 sec. (Table 1) 
VNS response based on the seizure frequency reported by patient or caregiver at baseline (mean of 1 - 3 months before implantation) and after one year 
(mean of 11 - 13 months after implantation). The patients were divided into one group with a seizure reduction of ≥ 50% (VNS responders) and one 
group with a seizure reduction < 50% (VNS non-responders). 
P3
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The P3 potential was measured via a 3-stimulus auditory oddball task with low-probability target stimuli (‘oddballs’), trains of high-probability stimuli 
(‘standards’) and low probability white noise stimuli (‘distractors’).  The signal can be divided into two components: the P3b component is evoked when 
the subject is responding to the target stimuli and reflects LC-NE activity, (13) whereas the P3a component appears as reaction to the distractor stimuli.
The P3b component was investigated in this study only at baseline in two conditions (VNS ON and VNS OFF). The test was conducted two times 
(randomized order), each lasted 20 minutes. Before initiating a task, the patient received either 20 min of VNS ON (current output 0.25-0.5mA, signal 
frequency 30Hz, pulse width 500µs, duty cycle: 7s ON-time and 18s OFF-time) or VNS OFF. The patients were seated in front of a computer screen and 
presented a series of auditory stimuli by running an E-Prime 2.0 script (Psychology Software Tools, Pittsburgh, PA, USA). Patients were instructed to press 
a button when the target sound was played, the standard sound and distractor were to be ignored. P3b amplitudes (µV) and latencies (ms) were calculated 
for all patients and analyzed in BRAIN VISION ANALYZER 2.0®.
HRV
HRV was calculated at baseline and after one year of treatment via electrocardiogram (ECG) registration during a resting position of five minutes without 
ectopic beats or artefacts. Two time-domain parameters, the standard deviation of all N-N intervals (SDNN) and the root mean square of the successive 
N-N differences (RMSDD) and two frequency domain parameters (LF and HF power) were evaluated in MATLAB®. The SDNN reflects the standard 
deviation of ‘normal’ sinus beats, both sympathetic and parasympathetic power contribute to SDNN.(16) The RMSDD reflects beat-to-beat variance in 
heart rate and measures the vagal mediated changes of HRV. (21) The LF power (0.15Hz and 0.4Hz) reflects both sympathetic and parasympathetic 
activity, the HF power (0.15Hz to 0.4Hz) reflects parasympathetic activity.(22) The Pan Thompkins algorithm was used for time domain analysis and the 
wavelet transformation (WT) with a Morlet mother wavelet for frequency domain analysis in the HF and LF spectrum. The Morlet mother wave technique 
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has been described by Addison et al and is known to reflect a good time and frequency resolution for high and low frequency spectral components in HRV 
analyses.(23) 
Video-EEG recording /PSG
Video-EEG recording (48 hours) and PSG (first night) were performed at baseline and after one year of treatment. PSG signals recorded: airflow, 
abdominal and thoracic respirogram, oxygen saturation, EEG with 23 electrodes, ECG 2 electrodes under left and right clavicle, electro-oculogram (EOG) 
2 electrodes, chin electromyogram (EMG) 2 electrodes, position, video and microphone. American Academy of Sleep Medicine (AASM) recommended 
EEG montage was applied for PSG scoring.(24) Video-EEG monitoring (International 10-20 System, 23 electrodes, sampling rate 256Hz) allowed to 
detect seizures during the PSG night. The PSG data were analyzed via Analyse Manager (REMBRANDT, MICROMED®), video-EEG monitoring 
recordings were analyzed in SYSTEMPLUS, MICROMED®. Scoring /analysis of PSG and video-EEG monitoring was performed by a neurologist 
experienced in sleep medicine and epilepsy (SH), blinded to VNS response after one year. Sleep stages (NREM 1, NREM 2, NREM 3 and REM sleep) in 
percent of total sleep time (TST) and apnea/hypopnea index (AHI) (events/hour) were evaluated at baseline and after one year of VNS. 
Statistics
A linear mixed model analysis compound symmetry was performed via SPSS 25 with patient number as a random effect. As fixed variables and covariates, 
time (baseline/one year after treatment), VNS response after one year, sleep influencing medication (benzodiazepines, antidepressants, neuroleptics and 
barbiturates), changes in AED, seizures during PSG night and age at implantation were considered. Sleep stages, AHI, HRV and P3b parameters were 
dependent variables. A p-value of 0.05 was regarded as statistically significant. 95% confidence interval was included. 
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RESULTS
Subjects and VNS 
Thirty adult DRE patients selected for VNS treatment were included in the study. Fourteen patients could not be included: VNS as status epilepticus 
treatment (one patient), local infection post VNS implantation (one patient), two patients died (one POLG 1 mutation, one unknown reasons), 10 patients 
did not participate or chose to be removed from the study. Mean age at implantation was 39.57 years (17 to 69 years, 14 female). Fifteen/30 patients were 
VNS responders one year following start of VNS. Detailed information on the subjects can be found in Table 1.
P3
In a subset of 13 patients (5/13 VNS responders) P3b was recorded and analyzed at baseline. The P3b amplitude in the VNS OFF condition was 
significantly lower at baseline in VNS responders (p=0.025) compared to VNS non-responders. VNS responders had a mean P3b amplitude of 
3.5µV (95% CI 0.9-6.0), whereas VNS non-responders had a mean P3b amplitude of 7.3µV (95% CI 5.3-9.3). (Figure 2) (Table 2) The P3b amplitude in 
the VNS ON condition was not significantly different in VNS responders compared to VNS non-responders and the change of P3b amplitude between 
VNS OFF and VNS ON condition was not significant. 
 Figure 2: P3b amplitude and VNS response. Means +/- 95% CI. 
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HRV
The HF power was significantly lower in VNS responders compared to VNS non-responders, both at baseline (p=0.03) and after one year of 
VNS (p=0.021). VNS responders had a mean HF power of 0.25Hz (95% CI 0.21-0.28) at baseline / 0.24Hz (95% CI 0.21-0.28) after one year and VNS 
non-responders had a mean HF power of 0.31Hz (95% CI 0.27-0.34) at baseline / 0.29Hz (95% CI 0.25-0.32) after one year. (Figure 3) (Table 2) No 
significant difference was found in time domain (SDNN and RMSSD) and frequency domain (LF and HF power) variables between baseline and one year 
of VNS.
 Figure 3: HF power baseline/one year of VNS and VNS response. Means +/- 95% CI. 
PSG 
The amount of NREM 3 was significantly higher in VNS responders at baseline (p=0.007) and after one year of treatment (p=0.001). VNS 
responders had a mean NREM 3 of 29% (95% CI 23.17-34.87) at baseline / 29% (95% CI 25.00-33.93) after one year and VNS non-responders had a 
mean NREM 3 of 17% (95% CI 11.49-23.19) at baseline / 18% (95% CI: 13.56–22.49) after one year. (Figure 4)
Other sleep stages did not differ significantly between VNS responders and VNS non-responders and did not change significantly due to VNS treatment. 
(Table 2) The AHI was significantly increased after one year of VNS treatment compared to baseline (p=0.04). Twenty-two/30 patients had an increase in 
AHI. Four patients developed mild obstructive sleep apnea syndrome (OSAS with AHI 5 - 15/hour). (Table 2)
 Figure 4: NREM 3 baseline and VNS response. Means +/- 95% CI. 
AED change 
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Thirteen/30 patients had a change of their AED treatment in the year following VNS implantation due to AED-related side effects or seizure 
exacerbation. (Table 1) A change in AEDs within the first year after start of VNS had a statistically significant influence on the increase in AHI observed 
after a year of VNS treatment (p=0.03).
Sleep influencing medication/seizures during PSG
Detailed information on drug changes and seizures can be found in Table 1. A significant decrease in NREM 2 due to change in sleep influencing 
medication could be observed (p=0.04). Seizures during the PSG led to a significant decrease of REM sleep (p=0.006). 
DISCUSSION
Although VNS treatment is a well-established therapy for DRE, responsiveness to the therapy is unpredictable. Given the typical heterogeneity both in the 
characteristics of VNS candidates and the effectiveness of VNS therapy, there is an urgent need for individualized response prediction.
 In this prospective study we provide novel results on neurophysiological parameters chosen based on the MOA of VNS, that were significantly different 
in VNS responders prior to therapy initiation. VNS responders were characterized by a significantly lower P3b amplitude, a significantly lower HF power 
and significantly more NREM 3. This suggests the existence of a differential state of the ‘vagal afferent network’ in responders, making a subgroup of DRE 
patients responsive to the seizure suppressing effect of VNS. 
The P3b component is linked to LC activity but also reflects the temporo-parietal junction integrity involving structures like the hippocampus with 
essential functions in memory storage procedures.(25) Murphy et al described that LC noradrenergic activity is reflected by the P3b component (26) and 
the reduced or absent integrity of the temporal-parietal junction leads to a severe decrease or loss of the P3b amplitude. (27, 28) The HF power of HRV 
reflects the activity of the vagus nerve ie. the parasympathetic influence on the heart. Several neuroimaging studies have described that the medial 
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prefrontal cortex, anterior cingulate, putamen and amygdala are involved in the cortical control of HRV. (14, 29) Sakaki et al described that higher 
functional connectivity between amygdala and medial prefrontal cortex are correlated with a higher HRV. (14) A recent neuroimaging study showed that 
high MRI contrast (neuromelanin-sensitive-weighted) in the LC, due to increased activity and reflecting a higher sympathetic tone is correlated with a lower 
HF power. (30) HF power is therefore correlated both to LC activity and limbic circuit brain structures. 
For the regulation of sleep the VLPO in the anterior hypothalamus plays a crucial role. (17) Experimental studies showed that lesions of the VLPO lead to 
a reduction of NREM and REM sleep of more than 50%. (31) The VLPO receives afferents from the LC, where noradrenaline has an inhibiting effect on 
VLPO neurons and induces wakefulness. (32) Intact thalamo-cortical functioning plays an important role during sleep and is mainly decreased during 
NREM sleep stadia. (19, 20, 33) The LC is still active at a decreased level during NREM 3 and only falls silent prior to each sleep spindle and during REM 
sleep (18); it provides direct input to the thalamo-cortical circuit. The unusual high amount of NREM 3 with a mean amount of 29% of TST in VNS 
responders compared to about 20% in healthy individuals might be linked to a decreased LC activity but also a disturbed functional connectivity of the 
thalamo-cortical circuit might lead to this phenomenon. Functional and structural alterations of the thalamo-cortical connections are known to be involved 
in seizure generation and propagation and therefore believed to represent an important substrate of VNS responsiveness. (34-36) Recent neuroimaging 
studies on resting-state fMRI prior to VNS implantation in children found an enhanced connectivity of the thalami to the anterior cingulate cortex and left 
insula in VNS responders, stating that network connectivity differs in between epilepsy patients and is associated with treatment response.(37) Stereo-
electroencephalography (SEEG) and high-density (HD) EEG studies have demonstrated that epileptic subcortico-cortical networks differ among epilepsy 
patients and some patterns may be associated with response to treatments affecting these networks such as VNS. (38, 39) The results of two of the three 
neurophysiological parameters investigated in this study (NREM 3, P3b) could be explained by a decreased LC activity, whereas the HF power results 
either reflect an increase in LC activity suggesting a more complex network connectivity pattern involving other structures of the vagal afferent network in 
this subpopulation. This complex network is also mentioned in major depression disorder (MDD), another approved indication for VNS treatment, where 
the target key structures (prefrontal cortex, cingulate cortex) belong to the vagal afferent network and stimulation of these regions is associated with 
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improvement of MDD. (40) Low HRV parameters, which normalize after neuromodulation treatment have been observed in MDD and provide a 
potential target engagement mechanism for optimizing neuromodulation treatments in depression. (41-43)
These three non-invasive, easy to perform neurophysiological tests provide additional strength in clinical practice supplementary to neuroimaging, HD 
EEG and SEEG to guide decision making in VNS treatment. We are aware of the fact that making individual decisions towards a selection of patients for 
VNS implantation based on these neurophysiological parameters alone is not feasible in current clinical practice due to the overlapping confidence 
intervals. A larger amount or an optimal combination of different characteristics involving different investigations may be required to create a successful 
predictive model for VNS response. 
P3 amplitude, HRV HF power and NREM 3 were not affected after one year of VNS treatment. It is known that several polymorphisms in NA-related 
genes predispose to the development of neuropsychiatric disorders or correlate with treatment response.(44) A variability in noradrenaline receptors or the 
efficacy of the noradrenaline reuptake transporter may underlie the association between P3, HRV, NREM3 and clinical response. We hypothesize that 
these neurophysiological parameters are individually determined characteristics that might predispose to VNS responsiveness but cannot necessarily be 
altered by the treatment. 
As described in several other studies, we found a significant increase of the AHI after one year of VNS (45, 46) in 22/30 patients. Four patients developed 
mild OSAS. A screening PSG for sleep disordered breathing before VNS treatment and follow-up PSG investigations in high-risk patients should be 
considered. 
LIMITATIONS OF THE STUDY
Following the initiation of VNS therapy, 1/3 of patients had a change in their AED treatment and 1/3 in sleep influencing medication. Although these 
drug changes may have played a role both on the long-term seizure control after one year of combined VNS and AED therapy and on sleep quality in 
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these patients, the changes itself did not affect our primary findings namely that a lower P3b amplitude, lower HRV HF power and more NREM 3 at 
baseline characterizes future responders to VNS therapy.
It is known that VNS therapy tends to improve with longer treatment duration reaching a plateau phase around 18 months.(47) In this prospective study 
we investigated neurophysiological parameters at start of VNS and after one year of treatment as this was a time point feasible for a prospective trial 
including neurophysiological investigations and considered long enough to distinguish clinical responders from non-responders. Prospective studies with 
even longer follow-up times may be required to corroborate our findings in the stage of the plateau phase. Our finding that responders and non-responders 
are different at onset of therapy should however not be affected by longer treatment periods.  Analysis of larger groups of VNS treated patients in whom 
baseline data such as sleep and ECG are available from pre-surgical video-EEG monitoring sessions could be of added value here.
CONCLUSION
This study is to our knowledge the first where easy to perform, non-invasive clinical tests, chosen based on the MOA of VNS, provide clinical 
characteristics of VNS responders that are significantly different from VNS non-responders. Prediction of response prior to implantation surgery is highly 
desirable in clinical practice. These non-invasive neurophysiological parameters add clinical value to neuroimaging, HD EEG and SEEG characteristics of 
VNS responders and should be implemented in decision making to guide neurostimulation strategies in DRE patients.(3) 
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Figure 1: Neurophysiological parameters linked to the VAN. HRV linked to prefrontal cortex (PFC), anterior cingulate cortex (ACC), amygdala (amyg), 
and Locus coeruleus (LC); Event related potential (ERP) P3b linked to LC; NREM 3 linked to thalamus (thal), hypothalamus (hyp), and LC; insula (ins), 
primary somatosensory cortex (S1), parabrachial nucleus (PB), dorsal raphe nucleus (DRN), nucleus tractus solitarius (NTS). Kate Campbell, Medical & 
Scientific Visualizations.
Figure 2: P3b amplitude and VNS response. Means +/- 95% CI. 
Figure 3: HF power baseline/one year of VNS and VNS response. Means +/- 95% CI. 
Figure 4: NREM 3 baseline and VNS response. Means +/- 95% CI. 
Patient 
Age (years) 
at 
implantatio
n 
Sex VNS model 
Type of 
Epilepsy 
Sleep 
influencing 
medication at 
baseline 
Antiepileptic drugs 
at baseline 
Change in AED within 1 
year 
Change in sleep 
influencing medication 
just before baseline 
/within 1 year 
Seizures during PSG 
night (PSG 1/PSG 2) 
AHI increase 
after 1 year 
VNS parameters 
after one year 
Current/duty 
cycle 
1 56 F 
 
103 Focal BZ/NL/ATD LEV/CBZ CBZ increase no/yes no/no yes 
1mA/30sec 
ON/3min OFF 
2 40 F 
 
103 Focal none OXC/LAC/VPA no no/no no/no yes 
1.25mA/30sec 
ON/10min OFF 
3 59 F 103 Multifocal BZ LEV/LAC no no/yes no/no yes 
1.25mA/30sec 
ON/10min OFF 
4 25 M 
 
103 Focal BZ LEV/CBZ/LAC no no/no no/no yes 
2mA/30sec 
ON/10min OFF 
5 19 F 
 
103 Focal BZ/NL/ATD CBZ/VGB no no/yes no/yes no 
1.75mA/30sec 
ON/5min OFF 
6 55 F 
 
103 Focal BZ/NL/ATD LTG/LAC no no/yes no/no yes 
1mA/30sec 
ON/10min OFF 
7 36 M 
 
103 Focal ATD VPA/PER/LEV PER stop, LTG start no/no no/no yes 
2.75mA/30sec 
ON/5min OFF 
8 43 M 
 
103 Focal BZ TPM/LTG/LAC/OXC no no/no no/no yes 
1.5mA/30sec 
ON/3min OFF 
9 69 M 103 Focal BZ CBZ/LEV/VPA/LAC 
VPA increase, LAC 
decrease no/yes no/no yes 
2mA/30sec ON/ 
5min OFF 
10 40 M 
 
103 Focal BZ CBZ/LAC no no/no no/no yes 
2.5mA/30sec 
ON/5min OFF 
11 29 M 103 Multifocal none VPA/TPM/LAC no no/no no/no yes 
1.75mA/30sec 
ON/ 1.8min OFF 
12 36 F 
 
103 Focal none LEV/PHT/TPM LEV decrease no/no no/no yes 
2.25mA/30sec 
ON/ 5min OFF 
13 69 F 103 Multifocal BZ CBZ/LEV/TPM CBZ decrease no/no no/no no 
0.75mA/30sec 
ON/ 10min OFF 
14 46 M 103 Multifocal BZ/NL CBZ/VPA/PHT/PB no no/yes no/no no 
0.75mA/ 30sec 
ON/10min OFF 
15 38 F 
 
103 Focal BZ CBZ/LEV/LTG/LAC LAC decrease no/no no/no yes 
1.25mA/30sec 
ON/5min OFF 
16 38 F 103 Multifocal BZ LEV/LAC/TPM LAC increase yes/yes no/no no 
2.25mA/30sec 
ON/5min OFF 
17 45 F 
 
103 Focal BZ/ATD PGB/LAC LAC stop, CBZ start no/yes no/no yes 
2mA/ 30sec ON/ 
10min OFF 
18 28 F 103 Focal BZ LEV/PGB/LAC 
LAC decrease, PGB 
increase no/no no/no yes 
2.75mA/30sec 
ON/ 5min OFF 
19 41 M 
 
103 Focal BZ VPA/CBZ/TPM no no/yes no/no yes 
1mA/ 30sec ON/ 
5min OFF 
20 28 F 106 Focal BZ CBZ/RTG 
CBZ increase, start 
BRV,RTG stop no/no yes/yes yes 
0.75mA/30sec 
ON/ 5min OFF 
21 27 M 106 Focal BZ/ATD 
 
CBZ/LAC/TPM/LEV no no/no yes/yes no 
1.25mA/30sec 
ON/ 5min OFF 
22 54 M 103 Multifocal BZ/ATD LEV/VPA LEV decrease no/no yes/no yes 
2mA/30sec 
ON/10min OFF 
23 44 M 
 
103 Focal BZ/ NL LAC/VPA/LEV LEV increase, LAC stop no/yes no/no yes 
1.5mA/30sec 
ON/ 10min OFF 
24 17 M 103 Multifocal BZ LEV no no/no yes/yes yes 
2.25mA/30sec 
ON/ 5min OFF 
25 30 M 
 
103 Focal none VPA/LAC/TPM no no/no no/no yes 
1.75mA/30sec 
ON/5min OFF 
26 34 F 103 Multifocal none LEV/TPM/OXC OXC increase yes/no yes/yes yes 
1.375mA/ 30 sec 
ON/5 min OFF 
27 39 M 106 Focal BZ 
 
VPA/LEV/PGB/OXC no no/no yes/yes yes 
1.75mA/ 30 sec 
ON/5min OFF 
28 59 F 106 Focal none 
 
CBZ no no/no no/no no 
1.875mA/ 30sec 
ON/5min OFF 
29 20 M 106 Focal BZ 
 
PHT/LEV/CBZ/LAC no no/no yes/no no 
2mA/30sec 
ON/5min OFF 
30 23 M 106 Multifocal BZ LEV/VPA/LAC/TPM no no/yes no/yes no 
2mA/30sec 
ON/5min OFF 
 
 Patients NREM 1 
(% of TST) 
baseline 
NREM 1 
(% of TS) 
after 1 
year 
VNS 
NREM 2 
(% of 
TST) 
baseline 
NREM 2 
(% of 
TST) after 
1 year 
VNS 
NREM 3 
(% of 
TST) 
baseline  
NREM 3 
(% of TST) 
after 1 
year VNS 
REM         
(% of TST) 
baseline 
REM         
(% of TST) 
after 1 
year VNS 
AHI 
baseline 
AHI     
after 1 
year 
VNS 
HF 
power 
(Hz) 
baseline 
HF power 
(Hz) after 1 
year VNS 
P3b 
amplitude 
(µV) 
baseline 
1 9.1 7.0 51.7 43.5 27.1 23.6 12.1 25.9 .3 2.1 0.27 0.3   
2 16.3 5.6 57.3 47.1 5.9 29.6 20.5 17.7 5.5 3.7 0.3 0.25   
3 2.4 5.3 78.5 57.8 7.5 17.2 11.5 19.7 .2 .9 0.26 0.17 6.41 
4 2.2 5.0 45.3 51.6 38.4 29.4 14.1 14.0 .5 .8 0.15 0.15   
5 5.0 3.4 53.6 54.9 20.7 21.3 20.7 20.4 .4 .1 0.28 0.3 6.53 
6 16.6 1.9 59.9 55.4 7.1 36.0 16.5 6.6 .5 1.5 0.3 0.34 7.58 
7 3.8 2.9 66.1 71.2 18.6 8.2 11.6 17.7 .8 2.0 0.28 0.26 6.97 
8 2.8 2.4 69.6 86.6 19.2 2.3 8.4 8.7 .0 1.3 0.26 0.29   
9 4.3 4.2 38.4 37.2 35.7 36.4 21.6 22.1 3.5 14.7 0.34 0.15 0.36 
10 3.2 3.8 47.3 59.2 34.8 32.4 14.7 4.6 3.0 6.5 0.15 0.37   
11 8.8 2.6 45.5 37.5 33.9 31.6 11.7 28.3 2.7 4.7 0.35 0.3 2.96 
12 2.6 2.2 58.7 57.8 8.7 17.1 30.1 22.9 .8 1.2 0.32 0.29   
13 5.1 2.3 44.5 43.2 37.2 45.1 13.2 9.3 1.2 2.9 0.25 0.24   
14 2.4 2.2 41.5 27.8 39.6 42.4 16.5 27.6 10.6 4.3 0.26 0.29 2.86 
15 2.0 3.9 52.0 57.0 13.8 18.1 32.1 21.0 .8 1.1 0.15 0.24   
16 3.7 6.4 66.7 67.1 12.6 7.3 17.0 19.3 1.8 .5 0.29 0.28   
17 5.5 2.9 56.0 42.4 27.2 38.2 11.3 16.5 6.8 7.8 0.15 0.15 5.02 
18 .3 2.6 73.4 84.8 3.3 12.7 22.9 .0 1.9 6.2 0.37 0.35 6.14 
19 5.8 8.3 27.5 31.6 41.3 38.9 25.4 21.2 .8 3.5 0.38 0.33 2.66 
20 4.7 2.9 59.7 78.9 19.3 12.5 16.3 5.7 1.2 5.4 0.35 0.31 10.79 
21 6.1 4.9 59.0 63.3 29.9 31.7 5.0 .0 1.4 1.0 0.17 0.17   
22 3.0 3.2 40.8 60.8 30.1 9.4 26.1 26.5 .3 7.3 0.27 0.28   
23 2.4 1.9 73.2 43.4 6.3 35.4 18.1 19.3 1.5 2.3 0.21 0.16   
24 .8 9.2 52.0 62.5 43.7 28.2 3.5 .0 .7 4.0 0.32 0.27   
25 3.7 2.1 54.3 54.3 25.8 6.5 16.2 37.1 1.0 1.2 0.31 0.38 6.26 
26 5.3 5.1 61.4 53.9 10.7 20.1 22.6 20.8 .0 .7 0.37 0.19   
27 1.4 3.5 65.7 63.3 33.0 24.8 .0 8.4 1.8 2.3 0.17 0.19   
28 1.3 1.6 52.7 45.2 30.7 37.3 15.3 15.9 2.4 .8 0.33 0.33 11.75 
29 1.8 .6 67.4 56.8 18.3 20.3 12.4 22.3 1.6 .6 0.32 0.33   
30 2.1 1.7 67.0 78.9 15.0 15.3 15.9 4.1 .8 .4 0.39 0.32   
                            
>50% reduction in seizure frequency after one year of treatment        
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